Prifemilast, an Oral Phosphodiesterase 4B (PDE4B)-Selective Inhibitor, Demonstrates Rapid and Durable Efficacy With a Favorable Tolerability and Safety Profile in Moderate to Severe Plaque Psoriasis: Results From Phase 2 and 3 Trials

Conclusion

• Prifemilast provided rapid and durable improvements in the extent and severity of moderate to severe psoriasis with a favorable tolerability profile
• These findings support continued development of prifemilast as a potential oral treatment option for psoriasis and other IMIDs, including ulcerative colitis and Crohn’s disease

Authors

Lin Cai,* Kun Chen,* Linfeng Li, Litao Zhang, Hong Ren, Yumei Li, Lanying Qin, Liming Wu, Pingping Qin, Guoqiang Zhang, Rushan Xia, Yuzhen Li, Qinghua Zhu, Qian Zhu, Weifen Zhou, Jianzhong Zhang
*These authors contributed equally.

Citation

Cai L, et al. Prifemilast, an Oral Phosphodiesterase 4B (PDE4B)-Selective Inhibitor, Demonstrates Rapid and Durable Efficacy With a Favorable Tolerability and Safety Profile in Moderate to Severe Plaque Psoriasis: Results From Phase 2 and 3 Trials. Poster presented at: 26th Annual Fall Clinical Dermatology Conference; October 8–11, 2026; Las Vegas, NV. ClinicalTrials.gov: Psor-201 (NCT07707141) · Psor-301 (NCT07712705).

Prifemilast is an investigational agent and is not approved for use by any regulatory authority.